WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
Deborah
D
Cohan
Julia
J
Mwesigwa
Paul
P
Natureeba
Flavia
F
Aliba Luwedde
Veronica
V
Ades
Albert
A
Plenty
Abel
A
Kakuru
Jane
J
Achan
Tamara
T
Clark
Beth
B
Osterbauer
Moses
M
Kamya
Diane
D
Havlir
D000328:Adult; D000480:Alkynes; D044966:Anti-Retroviral Agents / Q000009:adverse effects*; D048588:Benzoxazines / Q000008:administration & dosage / Q000009:adverse effects; D001942:Breast Feeding; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D057915:Drug Substitution / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D061466:Lopinavir / Q000008:administration & dosage / Q000009:adverse effects; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology; D011480:Protease Inhibitors / Q000009:adverse effects*; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects; D014454:Uganda; D014944:World Health Organization; D000099227:Abacavir
D000480:Alkynes; D044966:Anti-Retroviral Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D061466:Lopinavir; D019829:Nevirapine; D011480:Protease Inhibitors; D019438:Ritonavir; D000099227:Abacavir; C098320:efavirenz